Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 18.6% in March

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 235,600 shares, a decrease of 18.6% from the February 28th total of 289,400 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 278,300 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of Eton Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals in the 4th quarter valued at approximately $133,000. Two Sigma Advisers LP bought a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at $662,000. Two Sigma Investments LP acquired a new position in shares of Eton Pharmaceuticals during the fourth quarter worth $1,498,000. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Eton Pharmaceuticals by 18.3% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock worth $141,000 after purchasing an additional 1,634 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its holdings in Eton Pharmaceuticals by 6.4% in the fourth quarter. Parkman Healthcare Partners LLC now owns 276,890 shares of the company’s stock valued at $3,688,000 after purchasing an additional 16,664 shares during the period. 27.86% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Trading Up 3.9 %

Shares of Eton Pharmaceuticals stock opened at $13.26 on Thursday. The firm’s 50 day moving average is $15.43 and its 200 day moving average is $12.07. The firm has a market capitalization of $355.61 million, a PE ratio of -60.27 and a beta of 1.37. Eton Pharmaceuticals has a 1 year low of $3.03 and a 1 year high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million. As a group, research analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current year.

Analyst Ratings Changes

ETON has been the subject of several analyst reports. Craig Hallum boosted their target price on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, March 19th. B. Riley restated a “buy” rating and set a $24.00 price objective (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.